Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins

Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19 disease. Therapeutic antibodies are being developed that interact with the viral spike proteins to limit viral infection of epithelium. We have applied a method to dramatically improve the performance of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Leach, Adam, Miller, Ami, Bentley, Emma, Mattiuzzo, Giada, Thomas, Jemima, McAndrew, Craig, Van Montfort, Rob, Rabbitts, Terence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131632/
https://www.ncbi.nlm.nih.gov/pubmed/34006961
http://dx.doi.org/10.1038/s41598-021-89887-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131632/
https://www.ncbi.nlm.nih.gov/pubmed/34006961
http://dx.doi.org/10.1038/s41598-021-89887-w

Ejemplares similares